Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD1 | P21728 | 10/20 | 0.35 |
| ▸ | HTR3A | P46098 | 1/20 | 0.33 |
| ▸ | MPL | P40238 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 2/20 | 0.32 |
| ▸ | RAB9A | P51151 | 2/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | HTR1A | P08908 | 2/20 | 0.31 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.31 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.31 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.31 |
| ▸ | CDK1 | P06493 | 1/20 | 0.31 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.31 |
| ▸ | GSK3B | P49841 | 1/20 | 0.31 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL998153 | 0.73 | MEN1 (0.32) | NPC1RAB9AMEN1KMT2A | |
| SCHEMBL3705796 | 0.71 | L3MBTL1 (0.33) | — | |
| SCHEMBL2530393 | 0.70 | OPRM1 (0.56) | NPC1RAB9AMEN1KMT2A | |
| SCHEMBL370860 | 0.67 | GRM4 (0.64) | NPC1RAB9ATDP1MEN1KMT2A | |
| SCHEMBL10921322 | 0.65 | KDM4E (0.46) | NPC1RAB9ATDP1 | |
| SCHEMBL13306675 | 0.63 | MEN1 (0.50) | NPC1RAB9ATDP1MEN1KMT2A | |
| SCHEMBL20723182 | 0.63 | LRRK2 (0.33) | TDP1 | |
| SCHEMBL2535683 | 0.63 | PKM (0.47) | NPC1RAB9ATDP1MEN1KMT2A | |
| SCHEMBL2532768 | 0.63 | TRPV4 (0.60) | NPC1RAB9ATDP1MEN1KMT2A | |
| SCHEMBL370609 | 0.61 | MEN1 (0.63) | NPC1RAB9ATDP1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8513252-B2 | Pyrazole derivatives and their use as positive allosteric modulators of metabotropic glutamate receptors | ADDEX PHARMA S.A. (CH) | 2013-08-20 | — | — | US | claimed |
| EP-2456769-B1 | NOVEL PYRAZOLE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | ADDEX PHARMA SA (CH) | 2013-06-26 | — | — | EP | claimed |
| EP-2456769-A1 | NOVEL PYRAZOLE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | Addex Pharma SA (CH) | 2012-05-30 | — | — | EP | claimed |
| US-20120122907-A1 | Novel Pyrazole Derivatives and their use as Positive Allosteric Modulators of Metabotropic Glutamate Receptors | NISSAN MOTOR CO., LTD. (JP) | 2012-05-17 | — | — | US | claimed |
| US-8513252-B2 | Pyrazole derivatives and their use as positive allosteric modulators of metabotropic glutamate receptors | ADDEX PHARMA S.A. (CH) | 2013-08-20 | — | — | US | disclosed |
| EP-2456769-B1 | NOVEL PYRAZOLE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | ADDEX PHARMA SA (CH) | 2013-06-26 | — | — | EP | disclosed |
| EP-2456769-A1 | NOVEL PYRAZOLE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | Addex Pharma SA (CH) | 2012-05-30 | — | — | EP | disclosed |
| US-20120122907-A1 | Novel Pyrazole Derivatives and their use as Positive Allosteric Modulators of Metabotropic Glutamate Receptors | NISSAN MOTOR CO., LTD. (JP) | 2012-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120122907-A1 | Novel Pyrazole Derivatives and their use as Positive Allosteric Modulators of Metabotropic Glutamate Receptors | GRM1, GRM4, GRM3 | DRD1 533/4885HTR3A 325/4885MPL 2611/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.